SLS vs ZBIO: stock comparison and AI forecast
Sellas Life Sciences Group, Inc. (SLS) and Zenas Biopharma, Inc. (ZBIO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
SLS Sellas Life Sciences Group, Inc.
- Price
- $7.88 +59.8% · 6M
- Market Cap
- $1.59B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ZBIO Zenas Biopharma, Inc.
- Price
- $25.93 +24.5% · 6M
- Market Cap
- $1.69B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- SLS and ZBIO have similar market capitalizations ($1.59B and $1.69B).
- Over the last six months SLS returned +59.8% and ZBIO +24.5%.
- ZBIO carries 2.18 times debt per unit of equity, against 0.06 times for SLS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | SLS | ZBIO |
|---|---|---|
| Market Cap | $1.59B | $1.69B |
| P/B Ratio | 11.55x | 7.96x |
| EPS | $-0.23 | $-10.85 |
| Book Value/Share | $0.68 | $3.26 |
| FCF/Share | – | $-3.73 |
Profitability & Margins
| Metric | SLS | ZBIO |
|---|---|---|
| ROE | -23.6% | -255.2% |
| ROA | -22.3% | -80.2% |
| ROIC | -25.6% | -86.1% |
| Operating Margin | – | -4785.5% |
| Net Margin | – | -4925.5% |
| EBT Margin | – | -4923.1% |
| Tax Rate | – | -0.1% |
Financial Health
| Metric | SLS | ZBIO |
|---|---|---|
| Current Ratio | 18.83x | 9.42x |
| D/E Ratio | 0.06x | 2.18x |
| Financial Leverage | 1.06x | 3.18x |
| Interest Coverage | -122.1x | -50.2x |
| Working Capital | $135M | $539M |
Cash Flow
| Metric | SLS | ZBIO |
|---|---|---|
| Operating Cash Flow | -$28M | -$243M |
| Free Cash Flow | – | -$243M |
| Capital Spending | – | $0.00M |
Income Statement
| Metric | SLS | ZBIO |
|---|---|---|
| Operating Income | -$35M | -$526M |
| Net Income | -$32M | -$542M |
| R&D Expense | $20M | $238M |
| SG&A Expense | $12M | – |
| Cost of Goods Sold | $0.00M | – |
Dividend & Shareholder Information
| Metric | SLS | ZBIO |
|---|---|---|
| Shares Outstanding | 202M | 65M |
SLS vs ZBIO: stock comparison and AI forecast
Which is bigger, SLS or ZBIO?
SLS and ZBIO have similar market capitalizations ($1.59B and $1.69B).
Which stock performed better over the last six months, SLS or ZBIO?
Over the last six months SLS returned +59.8% and ZBIO +24.5%.
Which one does Intratio's AI model rank higher, SLS or ZBIO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.